It's All Off: $160bn PfizerGan Deal Collapses On Latest US Treasury Edicts
This article was originally published in Scrip
Pfizer Inc. and Allergan PLC have terminated "by mutual agreement" their $160bn merger . The decision was driven by new US Treasury Department rules endorsed by President Barack Obama to prevent tax inversion deals that were announced on April 4, 2016.
You may also be interested in...
Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.